View Financial HealthAristo Bio-Tech and Lifescience 배당 및 자사주 매입배당 기준 점검 3/6Aristo Bio-Tech and Lifescience 수익으로 충분히 충당되는 현재 수익률 0.6% 보유한 배당금 지급 회사입니다.핵심 정보0.6%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향6%최근 배당 및 자사주 매입 업데이트공시 • Sep 24Aristo Bio-Tech and Lifescience Limited Approves Final Dividend for the Financial Year Ended March 31, 2024Aristo Bio-Tech and Lifescience Limited at its 19th Annual General Meeting held on September 20, 2024, approved to declare a final dividend of INR 0.4 per share (Rupees Forty Paisa only) per Equity share of INR 10 each for the financial year ended on March 31, 2024.Declared Dividend • Aug 30Dividend increased to ₹0.40Dividend of ₹0.40 is 60% higher than last year. Ex-date: 6th September 2024 Payment date: 20th October 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (26% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jun 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹91.00, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 64% over the past three years.분석 기사 • Jun 09Here's Why We Think Aristo Bio-Tech and Lifescience (NSE:ARISTO) Might Deserve Your Attention TodayThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹10.55 (vs ₹5.97 in FY 2025)Full year 2026 results: EPS: ₹10.55 (up from ₹5.97 in FY 2025). Revenue: ₹3.64b (up 14% from FY 2025). Net income: ₹71.8m (up 77% from FY 2025). Profit margin: 2.0% (up from 1.3% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth.공시 • May 22Aristo Bio-Tech and Lifescience Limited to Report Second Half, 2026 Results on May 29, 2026Aristo Bio-Tech and Lifescience Limited announced that they will report second half, 2026 results on May 29, 2026Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹99.00, the stock trades at a trailing P/E ratio of 18.3x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 76% over the past three years.New Risk • Nov 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.0% Last year net profit margin: 1.8% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹834.0m market cap, or US$9.31m). Minor Risks High level of debt (79% net debt to equity). Share price has been volatile over the past 3 months (7.9% average weekly change). Profit margins are more than 30% lower than last year (1.0% net profit margin).공시 • Nov 13Aristo Bio-Tech and Lifescience Limited to Report First Half, 2026 Results on Nov 14, 2025Aristo Bio-Tech and Lifescience Limited announced that they will report first half, 2026 results on Nov 14, 2025Buy Or Sell Opportunity • Oct 15Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 8.0% to ₹135. The fair value is estimated to be ₹110, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%.Buy Or Sell Opportunity • Sep 30Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 1.9% to ₹133. The fair value is estimated to be ₹110, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%.분석 기사 • Sep 18Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Soars 26% But It's A Story Of Risk Vs RewardAristo Bio-Tech and Lifescience Limited ( NSE:ARISTO ) shares have had a really impressive month, gaining 26% after a...Buy Or Sell Opportunity • Sep 12Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 20% to ₹136. The fair value is estimated to be ₹111, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%.Board Change • Sep 08Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. 2 independent directors (4 non-independent directors). Non- Executive Independent Director Rashmi Otavani was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Aug 18Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 08, 2025Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 08, 2025, at 15:00 Indian Standard Time.분석 기사 • Jul 03Take Care Before Diving Into The Deep End On Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO)With a price-to-earnings (or "P/E") ratio of 21.8x Aristo Bio-Tech and Lifescience Limited ( NSE:ARISTO ) may be...Buy Or Sell Opportunity • Jun 02Now 18% undervaluedOver the last 90 days, the stock has risen 61% to ₹142. The fair value is estimated to be ₹172, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks High level of debt (51% net debt to equity). Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (₹963.3m market cap, or US$11.3m).분석 기사 • May 31Estimating The Intrinsic Value Of Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO)Key Insights Aristo Bio-Tech and Lifescience's estimated fair value is ₹172 based on 2 Stage Free Cash Flow to Equity...New Risk • May 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹844.2m (US$9.86m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (₹844.2m market cap, or US$9.86m). Minor Risk High level of debt (51% net debt to equity).Buy Or Sell Opportunity • May 16Now 24% undervaluedOver the last 90 days, the stock has risen 11% to ₹130. The fair value is estimated to be ₹172, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.Buy Or Sell Opportunity • Apr 25Now 21% undervaluedOver the last 90 days, the stock has risen 1.1% to ₹137. The fair value is estimated to be ₹172, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.Buy Or Sell Opportunity • Apr 07Now 24% undervaluedOver the last 90 days, the stock has risen 1.7% to ₹131. The fair value is estimated to be ₹174, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.분석 기사 • Mar 27Do Aristo Bio-Tech and Lifescience's (NSE:ARISTO) Earnings Warrant Your Attention?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹110, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 69% over the past year.Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹105, the stock trades at a trailing P/E ratio of 12.2x. Average trailing P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 18% over the past year.분석 기사 • Feb 12Is Aristo Bio-Tech and Lifescience (NSE:ARISTO) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...New Risk • Jan 14New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹837.4m (US$9.67m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$10m (₹837.4m market cap, or US$9.67m). Minor Risk High level of debt (51% net debt to equity).Board Change • Dec 18Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non- Executive Independent Director Rashmi Otavani was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Buy Or Sell Opportunity • Dec 03Now 22% undervaluedOver the last 90 days, the stock has risen 44% to ₹143. The fair value is estimated to be ₹182, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹131, the stock trades at a trailing P/E ratio of 22.9x. Average trailing P/E is 33x in the Chemicals industry in India. Total returns to shareholders of 76% over the past year.분석 기사 • Oct 30Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Doing What It Can To Lift SharesWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider Aristo...Valuation Update With 7 Day Price Move • Oct 23Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹125, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 59% over the past year.공시 • Sep 24Aristo Bio-Tech and Lifescience Limited Approves Final Dividend for the Financial Year Ended March 31, 2024Aristo Bio-Tech and Lifescience Limited at its 19th Annual General Meeting held on September 20, 2024, approved to declare a final dividend of INR 0.4 per share (Rupees Forty Paisa only) per Equity share of INR 10 each for the financial year ended on March 31, 2024.New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (₹722.6m market cap, or US$8.62m). Minor Risk Short dividend paying track record (1 year of continuous dividend payments).공시 • Aug 30Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 20, 2024Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 20, 2024, at 15:00 Indian Standard Time.Declared Dividend • Aug 30Dividend increased to ₹0.40Dividend of ₹0.40 is 60% higher than last year. Ex-date: 6th September 2024 Payment date: 20th October 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (26% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.분석 기사 • Aug 22Is Aristo Bio-Tech and Lifescience (NSE:ARISTO) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...분석 기사 • Jun 29Potential Upside For Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Not Without RiskWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") above 33x, you may consider Aristo...Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹90.35, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 54% over the past year.New Risk • May 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹539.5m market cap, or US$6.49m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Paying a dividend despite having no free cash flows.Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹73.70, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 22% over the past year.분석 기사 • Mar 22If EPS Growth Is Important To You, Aristo Bio-Tech and Lifescience (NSE:ARISTO) Presents An OpportunityIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹68.50, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 22% over the past year.New Risk • Mar 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹372.0m market cap, or US$4.49m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.9% average weekly change).Valuation Update With 7 Day Price Move • Mar 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹71.80, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 1.8% over the past year.Valuation Update With 7 Day Price Move • Feb 14Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹80.05, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 11% over the past year.Valuation Update With 7 Day Price Move • Jan 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹85.00, the stock trades at a trailing P/E ratio of 16.2x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 6.3% over the past year.New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Share price has been highly volatile over the past 3 months (9.0% average weekly change). High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹564.0m market cap, or US$6.77m).Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹69.55, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 22x in the Chemicals industry in India.New Risk • Jun 13New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹382.3m market cap, or US$4.64m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.2% average weekly change).Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹64.00, the stock trades at a trailing P/E ratio of 30.1x. Average trailing P/E is 20x in the Chemicals industry in India.Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹70.75, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 19x in the Chemicals industry in India.Reported Earnings • Jan 30Full year 2022 earnings released: EPS: ₹2.90 (vs ₹2.15 in FY 2021)Full year 2022 results: EPS: ₹2.90 (up from ₹2.15 in FY 2021). Revenue: ₹1.66b (flat on FY 2021). Net income: ₹14.5m (up 35% from FY 2021). Profit margin: 0.9% (up from 0.6% in FY 2021).Board Change • Jan 30Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Surendra Lakhawat was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.공시 • Jan 30Aristo Bio-Tech and Lifescience Limited has completed an IPO in the amount of INR 130.5216 million.Aristo Bio-Tech and Lifescience Limited has completed an IPO in the amount of INR 130.5216 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 860,800 Price\Range: INR 72 Discount Per Security: INR 5.1336 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 860,800 Price\Range: INR 72 Discount Per Security: INR 5.1336 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 91,200 Price\Range: INR 72 Discount Per Security: INR 5.1336 Transaction Features: Regulation S지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 배당금 지급이 안정적인 반면, ARISTO 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.배당금 증가: ARISTO 의 배당금 지급이 증가했지만 회사는 3 년 동안만 배당금을 지급했습니다.배당 수익률 vs 시장Aristo Bio-Tech and Lifescience 배당 수익률 vs 시장ARISTO의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ARISTO)0.6%시장 하위 25% (IN)0.3%시장 상위 25% (IN)1.5%업계 평균 (Chemicals)0.8%분석가 예측 (ARISTO) (최대 3년)n/a주목할만한 배당금: ARISTO 의 배당금( 0.6% )은 Indian 시장에서 배당금 지급자의 하위 25%( 0.29% )보다 높습니다.고배당: ARISTO 의 배당금( 0.6% )은 Indian 시장에서 배당금 지급자의 상위 25%( 1.48% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 낮은 배당금 지급 비율 (5.7%)로 인해 ARISTO의 배당금 지급은 수익으로 충분히 충당됩니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 7.4% )이 낮기 때문에 ARISTO 의 배당금 지급은 현금 흐름으로 완전히 충당됩니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/27 06:40종가2026/06/17 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Aristo Bio-Tech and Lifescience Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Sep 24Aristo Bio-Tech and Lifescience Limited Approves Final Dividend for the Financial Year Ended March 31, 2024Aristo Bio-Tech and Lifescience Limited at its 19th Annual General Meeting held on September 20, 2024, approved to declare a final dividend of INR 0.4 per share (Rupees Forty Paisa only) per Equity share of INR 10 each for the financial year ended on March 31, 2024.
Declared Dividend • Aug 30Dividend increased to ₹0.40Dividend of ₹0.40 is 60% higher than last year. Ex-date: 6th September 2024 Payment date: 20th October 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (26% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.
Valuation Update With 7 Day Price Move • Jun 10Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹91.00, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 64% over the past three years.
분석 기사 • Jun 09Here's Why We Think Aristo Bio-Tech and Lifescience (NSE:ARISTO) Might Deserve Your Attention TodayThe excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹10.55 (vs ₹5.97 in FY 2025)Full year 2026 results: EPS: ₹10.55 (up from ₹5.97 in FY 2025). Revenue: ₹3.64b (up 14% from FY 2025). Net income: ₹71.8m (up 77% from FY 2025). Profit margin: 2.0% (up from 1.3% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 22% per year, which means it is tracking significantly ahead of earnings growth.
공시 • May 22Aristo Bio-Tech and Lifescience Limited to Report Second Half, 2026 Results on May 29, 2026Aristo Bio-Tech and Lifescience Limited announced that they will report second half, 2026 results on May 29, 2026
Valuation Update With 7 Day Price Move • Apr 21Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹99.00, the stock trades at a trailing P/E ratio of 18.3x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 76% over the past three years.
New Risk • Nov 24New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.0% Last year net profit margin: 1.8% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹834.0m market cap, or US$9.31m). Minor Risks High level of debt (79% net debt to equity). Share price has been volatile over the past 3 months (7.9% average weekly change). Profit margins are more than 30% lower than last year (1.0% net profit margin).
공시 • Nov 13Aristo Bio-Tech and Lifescience Limited to Report First Half, 2026 Results on Nov 14, 2025Aristo Bio-Tech and Lifescience Limited announced that they will report first half, 2026 results on Nov 14, 2025
Buy Or Sell Opportunity • Oct 15Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 8.0% to ₹135. The fair value is estimated to be ₹110, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%.
Buy Or Sell Opportunity • Sep 30Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 1.9% to ₹133. The fair value is estimated to be ₹110, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%.
분석 기사 • Sep 18Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Soars 26% But It's A Story Of Risk Vs RewardAristo Bio-Tech and Lifescience Limited ( NSE:ARISTO ) shares have had a really impressive month, gaining 26% after a...
Buy Or Sell Opportunity • Sep 12Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 20% to ₹136. The fair value is estimated to be ₹111, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 19%.
Board Change • Sep 08Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. 2 independent directors (4 non-independent directors). Non- Executive Independent Director Rashmi Otavani was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Aug 18Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 08, 2025Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 08, 2025, at 15:00 Indian Standard Time.
분석 기사 • Jul 03Take Care Before Diving Into The Deep End On Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO)With a price-to-earnings (or "P/E") ratio of 21.8x Aristo Bio-Tech and Lifescience Limited ( NSE:ARISTO ) may be...
Buy Or Sell Opportunity • Jun 02Now 18% undervaluedOver the last 90 days, the stock has risen 61% to ₹142. The fair value is estimated to be ₹172, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks High level of debt (51% net debt to equity). Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (₹963.3m market cap, or US$11.3m).
분석 기사 • May 31Estimating The Intrinsic Value Of Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO)Key Insights Aristo Bio-Tech and Lifescience's estimated fair value is ₹172 based on 2 Stage Free Cash Flow to Equity...
New Risk • May 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹844.2m (US$9.86m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Market cap is less than US$10m (₹844.2m market cap, or US$9.86m). Minor Risk High level of debt (51% net debt to equity).
Buy Or Sell Opportunity • May 16Now 24% undervaluedOver the last 90 days, the stock has risen 11% to ₹130. The fair value is estimated to be ₹172, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.
Buy Or Sell Opportunity • Apr 25Now 21% undervaluedOver the last 90 days, the stock has risen 1.1% to ₹137. The fair value is estimated to be ₹172, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.
Buy Or Sell Opportunity • Apr 07Now 24% undervaluedOver the last 90 days, the stock has risen 1.7% to ₹131. The fair value is estimated to be ₹174, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.
분석 기사 • Mar 27Do Aristo Bio-Tech and Lifescience's (NSE:ARISTO) Earnings Warrant Your Attention?Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Valuation Update With 7 Day Price Move • Mar 26Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹110, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 24x in the Chemicals industry in India. Total returns to shareholders of 69% over the past year.
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹105, the stock trades at a trailing P/E ratio of 12.2x. Average trailing P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 18% over the past year.
분석 기사 • Feb 12Is Aristo Bio-Tech and Lifescience (NSE:ARISTO) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
New Risk • Jan 14New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹837.4m (US$9.67m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$10m (₹837.4m market cap, or US$9.67m). Minor Risk High level of debt (51% net debt to equity).
Board Change • Dec 18Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non- Executive Independent Director Rashmi Otavani was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Buy Or Sell Opportunity • Dec 03Now 22% undervaluedOver the last 90 days, the stock has risen 44% to ₹143. The fair value is estimated to be ₹182, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 47% over the last year. Earnings per share has grown by 50%.
Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹131, the stock trades at a trailing P/E ratio of 22.9x. Average trailing P/E is 33x in the Chemicals industry in India. Total returns to shareholders of 76% over the past year.
분석 기사 • Oct 30Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Doing What It Can To Lift SharesWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider Aristo...
Valuation Update With 7 Day Price Move • Oct 23Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹125, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 59% over the past year.
공시 • Sep 24Aristo Bio-Tech and Lifescience Limited Approves Final Dividend for the Financial Year Ended March 31, 2024Aristo Bio-Tech and Lifescience Limited at its 19th Annual General Meeting held on September 20, 2024, approved to declare a final dividend of INR 0.4 per share (Rupees Forty Paisa only) per Equity share of INR 10 each for the financial year ended on March 31, 2024.
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (₹722.6m market cap, or US$8.62m). Minor Risk Short dividend paying track record (1 year of continuous dividend payments).
공시 • Aug 30Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 20, 2024Aristo Bio-Tech and Lifescience Limited, Annual General Meeting, Sep 20, 2024, at 15:00 Indian Standard Time.
Declared Dividend • Aug 30Dividend increased to ₹0.40Dividend of ₹0.40 is 60% higher than last year. Ex-date: 6th September 2024 Payment date: 20th October 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (26% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend.
분석 기사 • Aug 22Is Aristo Bio-Tech and Lifescience (NSE:ARISTO) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
분석 기사 • Jun 29Potential Upside For Aristo Bio-Tech and Lifescience Limited (NSE:ARISTO) Not Without RiskWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") above 33x, you may consider Aristo...
Valuation Update With 7 Day Price Move • Jun 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹90.35, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 34x in the Chemicals industry in India. Total returns to shareholders of 54% over the past year.
New Risk • May 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (13% average weekly change). High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹539.5m market cap, or US$6.49m). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Paying a dividend despite having no free cash flows.
Valuation Update With 7 Day Price Move • Apr 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹73.70, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 22% over the past year.
분석 기사 • Mar 22If EPS Growth Is Important To You, Aristo Bio-Tech and Lifescience (NSE:ARISTO) Presents An OpportunityIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Valuation Update With 7 Day Price Move • Mar 20Investor sentiment improves as stock rises 25%After last week's 25% share price gain to ₹68.50, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 28x in the Chemicals industry in India. Total returns to shareholders of 22% over the past year.
New Risk • Mar 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹372.0m market cap, or US$4.49m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.9% average weekly change).
Valuation Update With 7 Day Price Move • Mar 05Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹71.80, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 1.8% over the past year.
Valuation Update With 7 Day Price Move • Feb 14Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₹80.05, the stock trades at a trailing P/E ratio of 15.3x. Average trailing P/E is 29x in the Chemicals industry in India. Total returns to shareholders of 11% over the past year.
Valuation Update With 7 Day Price Move • Jan 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹85.00, the stock trades at a trailing P/E ratio of 16.2x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 6.3% over the past year.
New Risk • Oct 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). Share price has been highly volatile over the past 3 months (9.0% average weekly change). High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹564.0m market cap, or US$6.77m).
Valuation Update With 7 Day Price Move • Jul 25Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹69.55, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 22x in the Chemicals industry in India.
New Risk • Jun 13New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 23% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.6x net interest cover). High level of non-cash earnings (23% accrual ratio). Market cap is less than US$10m (₹382.3m market cap, or US$4.64m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.2% average weekly change).
Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹64.00, the stock trades at a trailing P/E ratio of 30.1x. Average trailing P/E is 20x in the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Mar 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹70.75, the stock trades at a trailing P/E ratio of 33.2x. Average trailing P/E is 19x in the Chemicals industry in India.
Reported Earnings • Jan 30Full year 2022 earnings released: EPS: ₹2.90 (vs ₹2.15 in FY 2021)Full year 2022 results: EPS: ₹2.90 (up from ₹2.15 in FY 2021). Revenue: ₹1.66b (flat on FY 2021). Net income: ₹14.5m (up 35% from FY 2021). Profit margin: 0.9% (up from 0.6% in FY 2021).
Board Change • Jan 30Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Director Surendra Lakhawat was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
공시 • Jan 30Aristo Bio-Tech and Lifescience Limited has completed an IPO in the amount of INR 130.5216 million.Aristo Bio-Tech and Lifescience Limited has completed an IPO in the amount of INR 130.5216 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 860,800 Price\Range: INR 72 Discount Per Security: INR 5.1336 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 860,800 Price\Range: INR 72 Discount Per Security: INR 5.1336 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 91,200 Price\Range: INR 72 Discount Per Security: INR 5.1336 Transaction Features: Regulation S